Woodline Partners LP Sells 403,483 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Woodline Partners LP reduced its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 41.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 573,957 shares of the company's stock after selling 403,483 shares during the period. Woodline Partners LP owned 0.56% of Dyne Therapeutics worth $13,522,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Janus Henderson Group PLC raised its position in Dyne Therapeutics by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock worth $173,808,000 after purchasing an additional 566,146 shares during the last quarter. Geode Capital Management LLC grew its holdings in Dyne Therapeutics by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock worth $44,476,000 after acquiring an additional 27,916 shares during the period. Jefferies Financial Group Inc. acquired a new stake in Dyne Therapeutics during the 4th quarter worth about $42,408,000. Orbimed Advisors LLC grew its holdings in Dyne Therapeutics by 73.2% during the 4th quarter. Orbimed Advisors LLC now owns 1,227,080 shares of the company's stock worth $28,910,000 after acquiring an additional 518,680 shares during the period. Finally, Norges Bank acquired a new stake in Dyne Therapeutics during the 4th quarter worth about $22,384,000. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Up 0.8%

DYN stock traded up $0.10 during mid-day trading on Tuesday, reaching $11.79. 123,733 shares of the company traded hands, compared to its average volume of 2,393,064. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -3.31 and a beta of 1.19. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The firm's 50 day moving average price is $10.31 and its 200 day moving average price is $16.63.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Analyst Ratings Changes

DYN has been the subject of a number of recent analyst reports. Scotiabank initiated coverage on Dyne Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target for the company. Chardan Capital restated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday, May 9th. JPMorgan Chase & Co. reduced their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. HC Wainwright reduced their target price on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, BMO Capital Markets began coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $47.25.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.